Over 44 million people across the U.S. suffer from Dry Eye Disease of which 86% is due to Meibomian Gland Dysfunction (MGD). Access to innovative treatment is limited to patients willing to pay out-of-pocket. Join this informative webinar to learn what Sight Sciences is doing to improve patient access for services – and what YOU can do to partner in this important initiative towards patient care.